Our hospital Cardiac Surgery Director Wang Chunsheng and Sun Xiaoning, the team of chief physicians successfully completed the implantation of a ventricular assist device with the smallest body weight in China, and the patient Ms. Hu has been discharged from the hospital. In just 5 months, the Department of Cardiac Surgery in our hospital has completed 7 artificial heart clinical trials, ranking second in the country in number, and all have achieved good results.
Ms. Hu who underwent the operation weighed only 37 kilograms and suffered from dilated cardiomyopathy. For many years, Ms. Hu’s heart had insufficient ejection of blood, causing her breathing difficulties, edema, and fatigue. In recent months, when entering the decompensated stage of heart failure, heart function will deteriorate rapidly. Not only can you breathe out, but the liver and kidney functions also deteriorate rapidly, entering the stage of end-stage heart failure . The difficulty of treatment for Ms. Hu is that not only the drugs are ineffective, because the population reactivity antigen is too high, if heart transplantation is done, it is likely that rejection will occur, so she cannot accept heart transplantation; Seek doctors more often and learn that artificial heart is the last hope.
In February this year, the cardiac surgery team of our hospital completed the transplantation operation of the first ventricular assist device "Chinese Rocket Heart"-HeartCon implanted into patients with end-stage heart failure in East China. This marks a historic breakthrough in the treatment of patients with end-stage heart failure. Prior to Ms. Hu, the cardiac surgery team had successfully completed 6 cases of "China Rocket Heart" artificial heart transplantation, and the team's experience has become more and more abundant.
Faced with Ms. Hu's severe illness and light weight, light weight patients have lower requirements for cardiac output, and the minimum output of the artificial heart will exceed the patient's needs. The artificial heart will be maintained and adjusted after the operation. , The balance of incoming and outgoing water brings challenges. The team decided to face the difficulties, and after full preparation, formulated a thorough surgical plan. In the Department of Anesthesiology, Deputy Director Guo Kefang, in Cardiopulmonary Bypass Zhao Yun, Deputy Chief Physician,In the operating room, Cha Wanjun and nurse Yang Yue successfully implanted the left ventricle assistive device. The operation process went smoothly. In view of the patient's light weight and poor liver and kidney function coagulation mechanism, Ms. Hu was followed by a 24-hour relay care by the deputy director of Critical Care Medicine Coluozhe and the monitoring team of Zheng Jili and Chen Yihong. Deputy Chief Physician Dong Lili used super-fine and superb assessments to guide the monitoring and careful adjustment of medication, and overcome the difficulties in the rehabilitation process. Under the careful care of the nursing team, the machine runs smoothly and the patient is in good condition.
Compared with traditional heart transplantation, heart transplantation is to replace the patient with a completely new heart, while the artificial heart assist device replaces the work of the left ventricle and preserves the function of the patient’s right ventricle. It is necessary to balance the functions of the left and right ventricles, so It requires a strong comprehensive strength in critical care medicine as a support, as well as a team spirit in close cooperation among various disciplines.
According to the results of the 2019 China Cardiovascular Health and Disease Report, the current number of cardiovascular patients in my country is about 330 million, and the number of patients with central failure is 8.9 million, and the prevalence continues to increase. The best treatment for heart failure The plan is a heart transplant. Although the number of heart transplants continues to rise, it still cannot satisfy the huge population of heart failure patients in my country. Due to the severe shortage of heart donors, most patients with end-stage heart failure cannot receive heart transplantation at all. In the case of ineffective medical treatment, these patients can only wait helplessly for the arrival of death. Artificial heart is undoubtedly a dawn in the desperate night of patients, and it is also the last battle in the treatment of patients with heart failure.
The artificial heart assist device is a device that can help the weak heart of the patient to transport blood from the heart to the whole body, but it does not replace the heart of the patient, but shares part of the work of the heart. The artificial heart assist device can be used for short-term treatment before the appearance of a suitable donor heart, or it can be used permanently. The artificial heart assist device has two operating modes: charging and battery. The battery can be used during the day when the patient is active, and the artificial heart assist device is charged when the patient sleeps at night. In recent years, with the accumulation of experience in implanting left ventricular assist devices, the treatment results of left ventricular assist devices (LVAD) have become better and better.The 1-year survival rate has reached 90%.
With the development of China's artificial heart, the era of China's artificial heart is also coming. The “Chinese Rocket Heart” implanted by Ms. Hu is a left ventricular assist device with completely independent intellectual property rights in my country. It belongs to the most advanced third-generation implantable magnetic fluid suspension ventricular assist device. Implantable heart assist devices and total artificial hearts are not only auxiliary means of heart transplantation. For patients with advanced heart failure like Ms. Hu who are not suitable for heart transplantation and whose heart function is hopeless, long-term application of heart assist device treatment will be the last hope.
.-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-